CORESTEM, Inc
http://corestem.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CORESTEM, Inc
Cutting-Edge Biologics Approvals, Trials Pick Up In Korea After New Law
Novartis among the first to benefit with approvals for Zolgensma, Kymriah, and Luxturna. The new law has also enabled its first clinical trial – a Phase Ib study by Seoul National University of a CAR-T therapy for recurrent or refractory, CD19-positive, B-cell acute lymphoblastic leukemia.
ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
Treeway Goes To Phase III With ALS Oral Compound
Dutch biotech Treeway has completed its Phase I trial of lead program TW001, an oral formulation of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS) and will now prepare for a pivotal Phase III study.
Korean Pro-Innovation Pricing Steps Draw Mixed Responses
Amid pharma industry’s repeated calls to improve the drug pricing system and properly reflect R&D cost of novel drugs, South Korea released steps that include hiking prices of “global innovative novel drugs” and biomedicines. Response is mixed, with foreign pharmas complaining the steps focus mainly on domestically developed drugs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- CORESTEM, Inc.
- Corestem Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice